Pfizer drug beats AZ rival in halting lung cancer

05:27 EDT 6 Jun 2017 | Pharmafile

New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression of EGFR-positive non-small cell lung cancer (NSCLC), albeit with a higher prevalence of side-effects.

Like older treatments, dacomitinib targets abnormal epidermal growth factor receptor genes in advanced lung cancer. In a study of 452 patients, Pfizer’s drug exhibited the ability to delay the progression of cancer for 14.7 months, compared to 9.2 months for AZ’s Ingressa – a 41% improvement.

read more

Original Article: Pfizer drug beats AZ rival in halting lung cancer


More From BioPortfolio on "Pfizer drug beats AZ rival in halting lung cancer"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...